The protective effect of different-time-ischemic preconditioning on the reperfusion injury in fatty livers in rats

Tang JianJun; Jiang Yong; Luo GuangHua; Yuan Bo

Issue 12

Dec. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(12): 1308-1311

PDF( 1571 KB)

The protective effect of different-time-ischemic preconditioning on the reperfusion injury in fatty livers in rats

Research funding:

Published Date: 2011-12-20

Abstract

Abstract

Objective To elucidate the protective effect and potential mechanisms of preconditioning on hepatic IR injury in steatotic livers and explore the optimal ischemic time.Methods The fatty liver model was made by feeding high-fat diet.The changes in serum and in liver sample were evaluated for the different ischemic time of preconditioning liver.Histological analyses of liver were performed and hepatic fatty infiltration were evaluated by sudan III stain.Results 1.The preconditioning consisting of 15 minutes of ischemia followed by 10 minutes of reperfusion was performed (15 min +10 min IP) .The extent and number of necrosis areas at 24 hours after hepatic reperfusion was markedly increased in fatty livers.By contrast, the histological study in normal liver showed moderate.2.The level of serology and the changes of MDA, MPO in liver in 5 or 8-10 min preconditioning group were lower than the other preconditioning groups in fatty liver, while the SOD activity level was significantly higher than the others (P< 0.05) .The serological level of NO in IP group was significantly higher than the corresponding IR group (P< 0.05) .In fatty liver group, the level of NO in 5 or 8-10 min IP group was significantly higher than the others (P< 0.05) .Conclusion Liver with fat infiltration can aggravate ischemia-reperfusion injury in rats.Ischemia preconditioning can also increase the tolerance of fatty liver induced by high-fat diet to hepatic ischemia-reperfusion injury in rats.The protective effect of ischemia preconditioning is distinct in different ischemic time of preconditioning, and the 5-8 min and 10 min IP was superior to the others.
- fatty liver,
- ischemic preconditioning,
- reperfusion injury

FullText(HTML)

References(8)

References

[1] Rutherford A, Davern T, Hay JE, et al. Influence of high body mass index on outcome in acute liver failure[J]. Clin Gastroenterol Hepatol, 2006, 4 (12) : 1544-1549.

[2] Nakano H, Nagasaki H, Barama A, et al. The effects of N-acetylcysteine and anti-intercellular adhesion molecule-1 monoclonal antibody against ischemia-reperfusion injury of the rat steatotic liver produced by a choline-methionine-deficient diet[J]. Hepatology, 1997, 26 (3) : 670-678.

[3] Federico A, Trappoliere M, Loguercio C, et al. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives[J]. Dig Liver Dis, 2006, 38 (11) : 789-801.

[4] Camara-Lemarroy CR, Guzman-de la Garza FJ, Alarcon-Galvan G, et al. The effects of NMDA receptor antagonists over intestinal ischemia/reperfusion injury in rats[J]. Eur J Pharmacol, 2009, 621 (1-3) : 78-85.

[5] Lehmann TG, Wheeler MD, Froh M, et al.Effects of three superoxide dismutase genes delivered with an adenovirus on graft function after transplantation of fatty livers in the rat[J]. Transplantation, 2003, 76 (1) : 28-37.

[6]Rensen SS, Slaats Y, Nijhuis J, et al.Increased hepatic my-eloperoxidase activity in obese subjects with nonalcoholicsteatohepatitis[J].Am J Pathol, 2009, 175 (4) :1473-1482.

[7]Iniguez M, Dotor J, Feijoo E, et al.Novel pharmacologic strate-gies to protect the liver from ischemia-reperfusion injury[J].Recent Pat Cardiovasc Drug Discov, 2008, 3 (1) :9-18.

[8]Romanque P, Diaz A, Tapia G, et al.Delayed ischemic pre-conditioning protects against liver ischemia-reperfusion inju-ry in vivo[J].Transplant Proc, 2010, 42 (5) :1569-1575.

Relative Articles

[1]	Gonghai CHEN, Guangchuan WANG, Chunqing ZHANG. Current status of research on hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2021, 37(5): 1201-1204. doi: 10.3969/j.issn.1001-5256.2021.05.047
[2]	Huang Shan, Zhou Hao, Chen XueLing, Yao Xin, Tang ShanHong, Yang GuoDong, Qin JianPing. Effect of transjugular intrahepatic portosystemic shunt on the liver and the heart[J]. Journal of Clinical Hepatology, 2020, 36(4): 904-907. doi: 10.3969/j.issn.1001-5256.2020.04.043
[3]	Wang Zhong, Yue ZhenDong, Zhao HongWei, Wang Lei, Fan ZhenHua, Wu YiFan, Dong ChengBin, Zhang Yu, Liu FuQuan. Value of indocyanine green retention rate at 15 minutes in predicting the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in liver cancer patients with portal hypertension[J]. Journal of Clinical Hepatology, 2020, 36(9): 1994-1997. doi: 10.3969/j.issn.1001-5256.2020.09.017
[4]	Li Jing, Jiang Yong, Zhang Xu. Efficacy of transjugular intrahepatic portosystemic shunt versus endoscopic cyanoacrylate injection in treatment of gastric variceal bleeding: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(2): 349-353. doi: 10.3969/j.issn.1001-5256.2019.02.021
[5]	He ChuangYe, Chen Hui, Lyu Yong, Xia DongDong, Yu TianLei, Yuan XuLong, Li Kai, Wang ZhengYu, Niu Jing, Bai Wei, Guo WenGang, Tie Jun, Yin ZhanXin, Han GuoHong. Safety and efficacy of flow-reducing stent in treatment of recurrent or persistent hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(8): 1719-1722. doi: 10.3969/j.issn.1001-5256.2019.08.014
[6]	Wang Zhong, Liu FuQuan. Research advances in hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2019, 35(12): 2824-2827. doi: 10.3969/j.issn.1001-5256.2019.12.040
[7]	Ding ZhiFeng, Yin ShiWu, Zhang GuoBing, Wang MingQuan, Pan ShengQuan. Clinical effect of Viatorr stent versus double-stent technique in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(3): 579-582. doi: 10.3969/j.issn.1001-5256.2018.03.026
[8]	Jiang MingYuan, Huang Hua, Lu MingLiang, Lin FanYu, Zhang YingYuan. Application of anticoagulants after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(10): 2241-2244. doi: 10.3969/j.issn.1001-5256.2018.10.040
[9]	Ding ZhiFeng, Yin ShiWu. Application of Viatorr covered stent in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(5): 1107-1110. doi: 10.3969/j.issn.1001-5256.2018.05.039
[10]	Interventional Group, Chinese Society of Radiology, Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2017, 33(7): 1218-1228. doi: 10.3969/j.issn.1001-5256.2017.07.004
[11]	Zhang Wei, ZhuGe YuZheng, Zhang Ming, He QiBin, Zhang Feng, Wang Yi, Zou XiaoPing. Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(2): 259-263. doi: 10.3969/j.issn.1001-5256.2016.02.012
[12]	Xu Lu, Xiao Xue, Liu JingQi, Wang Jing, Zhou JingJing, Jiang ChunMeng. Influence of covered stent versus bare stent on long-term efficacy of transjugular intrahepatic portosystemic shunt: a Meta-analysis[J]. Journal of Clinical Hepatology, 2016, 32(10): 1900-1905. doi: 10.3969/j.issn.1001-5256.2016.10.015
[13]	Xue Hui, Li PeiJie, Li WeiZhi, Su JingWen, Huang Jin. Prevention and treatment of complications after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 238-241. doi: 10.3969/j.issn.1001-5256.2016.02.007
[14]	Xiao JiangQiang, ZhuGe YuZheng. Advances in transjugular intrahepatic portosystemic shunt and its application in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(2): 234-237. doi: 10.3969/j.issn.1001-5256.2016.02.006
[15]	Tuo Lin, Tang ShanHong, Zeng WeiZheng, Wu XiaoLing. Treatment and prevention strategies to complications of transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 354-357. doi: 10.3969/j.issn.1001-5256.2016.02.034
[16]	Niu Meng, Sun Jun, Xu Ke, Zhong HongShan. Retrospects and prospects of transjugular intrahepatic portosystemic shunt in China[J]. Journal of Clinical Hepatology, 2016, 32(2): 230-233. doi: 10.3969/j.issn.1001-5256.2016.02.005
[17]	Tang ShanHong, Qin JianPing, Jiang MingDe, Ceng WeiZheng, Yao Xin, He QianWen, Tang Wen, Gu Ming. Clinical effect and safety of TIPS in treatment of portal hypertension due to alcoholic cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(2): 145-148. doi: 10.3969/j.issn.1001-5256.2014.02.012
[18]	Jiang Hao, Xie Qing. Advances in the diagnosis and treatment of hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2011, 27(10): 1027-1031.
[19]	Wang YuMing, Yan ZeHui. The new concepts on hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2010, 26(6): 568-574.
[20]	Tang TongYu, Chen LiGang, Wu Yang. The value of visual evoked potential and psychometric tests in detection of subclinical hepatic encephalopathy.[J]. Journal of Clinical Hepatology, 2004, 20(6): 361-362.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2626) PDF downloads(674)

The protective effect of different-time-ischemic preconditioning on the reperfusion injury in fatty livers in rats

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The protective effect of different-time-ischemic preconditioning on the reperfusion injury in fatty livers in rats

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content